FDA approvedMetabolic

Tirzepatide

LY3298176 / Mounjaro (diabetes) / Zepbound (obesity)

FDA-approved dual GLP-1/GIP receptor agonist. Approved as Mounjaro for type 2 diabetes (2022) and Zepbound for obesity (2023). SURMOUNT trials showed approximately 21% average body-weight reduction at 15mg — outperforming semaglutide in head-to-head data. Developed by Eli Lilly. Compounding pathway effectively closed — Eli Lilly has aggressively pursued legal action against pharmacies compounding tirzepatide.

Evidence

Phase III / FDA approved

Routes

injectable

Available since

FDA approved as Mounjaro May 2022 and Zepbound November 2023. Developed by Eli Lilly.

Mechanism of action

Activates GLP-1 receptors driving insulin secretion and appetite suppression, plus GIP receptors enhancing insulin response and fat metabolism. The dual mechanism produces greater metabolic effects than GLP-1 agonism alone. Administered weekly via subcutaneous injection with a half-life supporting once-weekly dosing. Different from semaglutide (GLP-1 only) and retatrutide (triple agonist).

Effects in the body

Tirzepatide is the FDA-approved upgrade from semaglutide for many patients. SURMOUNT Phase 3 trials showed approximately 21% average body-weight reduction at the 15mg dose — exceeding semaglutide's approximately 15% in comparative data. Dr. Abud Bakri and Dr. Andrew Huberman discussed tirzepatide on the Huberman Lab podcast (June 1, 2026) — covering GLP-1 discovery, physical and cognitive long-term effects, fertility considerations, and what the research shows beyond weight loss headlines. Notable finding from trials: significant muscle mass loss documented alongside fat loss — requires protein intake and resistance training attention during use.

Pros & cons (from the literature)

Pros

FDA approved — highest regulatory standing
SURMOUNT Phase 3 trials completed with robust human safety and efficacy data
21% average weight reduction exceeds semaglutide in comparative data
Once-weekly injection
Approved for both type 2 diabetes (Mounjaro) and obesity (Zepbound)
Dual GLP-1/GIP mechanism more effective than single-receptor agonists

Cautions

Compounding pathway effectively closed — Eli Lilly has aggressively pursued legal action against pharmacies compounding tirzepatide
Brand cost significant without insurance coverage
Nausea vomiting and GI side effects common especially during dose escalation
Significant muscle mass loss documented alongside fat loss — protein and resistance training essential
Requires physician prescription
Fertility implications — not recommended during pregnancy

Protocol summary (from published research)

FDA-approved dosing: start at 2.5mg weekly subcutaneous injection, titrate by 2.5mg every 4 weeks to target dose of 5-15mg weekly depending on indication and tolerance. Dose escalation manages GI side effects. Requires physician supervision and monitoring.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

FDA approved as Mounjaro (type 2 diabetes, May 2022) and Zepbound (obesity, November 2023). Compounding pathway is effectively closed — Eli Lilly has filed federal lawsuits against compounding pharmacies preparing tirzepatide, and courts have largely sided with the manufacturer. Unlike semaglutide (where a shortage window briefly opened compounding), tirzepatide compounding access is severely restricted. Prescription from a licensed physician and brand dispensing is the legally defensible pathway.

Evidence base

Multiple completed Phase 3 RCTs. SURMOUNT-1 and SURMOUNT-2 obesity trials published. SURPASS diabetes trial series completed. Full FDA review completed. One of the most robustly evidenced metabolic compounds available.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.